Oculis Holding AG
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OCS research report →
Range $26 – $45
Price Chart
About the company
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease.
- CEO
- Riad Sherif
- IPO
- 2021
- Employees
- 60
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on OCS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $435.83M
- P/E
- -4.27
- PEG
- -0.09
- P/S
- 51935.74
- P/B
- 1.74
- EV/EBITDA
- -3.77
- Div Yield
- 0.00%
- Gross Margin
- -2149.06%
- Op Margin
- -1293091.53%
- Net Margin
- -1157669.73%
- ROE
- -39.51%
- ROIC
- -42.43%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-79,145,361
- Net Income
- $-94,508,181-10.2%
- EPS
- $-1.81+14.6%
- OCF Growth
- -31.0%
- FCF Growth
- -31.0%
- 52W High
- $34.48
- 52W Low
- $6.78
- 50D MA
- $8.40
- 200D MA
- $17.45
- Beta
- 0.23
- RSI (14)
- 42
- Avg Volume
- 270.35K
No earnings-call transcripts are available for OCS yet.
- Free Float
- 64.8%
- Shares Outstanding
- 61.73M
- Float Shares
- 39.99M
of shares held by institutions
62 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eqt Fund Management S.A R.L. | 6.95M | 0 |
| Aberdeen Group PLC | 2.28M | ▲ 118.56K |
| Millennium Management LLC | 2.24M | ▲ 199.49K |
| Pivotal Bioventure Partners Investment Advisor LLC | 1.66M | ▲ 152.66K |
| Braidwell LP | 1.07M | ▲ 234.70K |
| Citadel Advisors LLC | 964.96K | ▼ 22.24K |
| Franklin Templeton Inc | 897.16K | ▲ 462.41K |
| Saturn V Capital Management LP | 847.44K | ▲ 162.56K |
| Ameriprise Financial Inc | 772.42K | ▲ 152.50K |
| Sr One Capital Management, LP | 641.02K | 0 |
| Siren, L.L.C. | 625.00K | 0 |
| Qube Research & Technologies Ltd | 470.65K | ▲ 208.53K |
Held by 10 ETFs
Biggest fund positions in OCS by dollar value.
Our OCS coverage
Recent articles, reports, and earnings notes.
No research on OCS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OCS report →Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
globenewswire.com · Nov 16
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
globenewswire.com · Nov 13
Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet
zacks.com · Nov 12
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
globenewswire.com · Nov 9
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
globenewswire.com · Nov 9
Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround
zacks.com · Nov 6
Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 3
Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
globenewswire.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.